

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Douglas ROSS et al.

Application No.: 09/961,086

Filed: September 21, 2001

For: BREAST CANCER RESISTANCE
PROTEIN (BCRP) AND THE DNA
WHICH ENCODES IT



Group Art Unit: 1642

Examiner: Unassigned

Confirmation No.: 6592

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By Jennifer A. Topmiller
Jennifer A. Topmiller, Ph.D.
Registration No. 50,435

Date: February 20, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Douglas ROSS et al.

Application No.: 09/961,086

Filed: September 21, 2001

For: BREAST CANCER RESISTANCE
PROTEIN (BCRP) AND THE DNA
WHICH ENCODES IT



)
)
) Group Art Unit: 1642

)
) Examiner: Unassigned

)
) Confirmation No.: 6592

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore under 37 C.F.R. § 1.97(b) no fee or statement is required.


To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: February 20, 2003

By:


Jennifer A. Topmiller, Ph.D.
Registration No. 50,435

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

APPLICATION No.
09/961,086

FILING DATE
September 21, 2001

GROUP
1642

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FEB 20 2003

U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

[illegible]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	T. Gura, SCIENCE, Vol. 270, Oct. 27, 575-77, 1995, "Antisense Has Growing Pains"
	James U. Bowie et al., SCIENCE, Vol. 247, 1300-1310, Mar. 16, 1990
	Eliane Lazar et al., Molecular and Cellular Biology, Vol. 8, No. 3, p. 1247-1252, Mar. 1988
	Wilson H. Burgess et al., The Journal of Cell Biology, Vol. 111, 2129-2138, Nov. 1990
	Hillier et al. (W84773), Genbank Sequence Database (Accession W84357) Ntl. Ctr. for Biotech. Info., Natl. Lib. Medicine, Bethesda, MD, 1995

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.